[Skip to Content]
[Skip to Content Landing]
May 2, 1980

Chemotherapy for Advanced Male Breast Cancer

JAMA. 1980;243(17):1739-1741. doi:10.1001/jama.1980.03300430041021

An analysis of 29 chemotherapeutic trials in 18 male patients with advanced breast cancer disclosed an overall response rate of 44%. Most of these chemotherapeutic trials consisted of single-agent regimens, namely, fluorouracil, methotrexate, thiotepa, cyclophosphamide, and melphalan. Our data suggest that responsiveness of advanced male breast cancer to systemic chemotherapeutic agents is the same as that reported for advanced female breast cancer.

(JAMA 243:1739-1741, 1980)